Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1Lymphoid 1Head & Neck 1Genitourinary 1CNS 1Breast 1

Conditions

Sarcoma 17Glioblastoma 10Brain Neoplasms 10Gliosarcoma 9Rhabdomyosarcoma 7Osteosarcoma 7Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Sarcoma, Ewing 5Recurrence 5Leukemia, Myeloid, Acute 5Dendritic Cell Sarcoma, Interdigitating 5Burkitt Lymphoma 5Astrocytoma 5Oligodendroglioma 4Myeloproliferative Disorders 4Myelodysplastic Syndromes 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Lymphoma, Mantle-Cell 4Lymphoma, Follicular 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Leukemia 4Hodgkin Disease 4Glioma 4Rhabdoid Tumor 3Primary Myelofibrosis 3Neurofibrosarcoma 3Neuroblastoma 3

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Gemcitabine 1Etoposide 1Disulfides 1Cyclophosphamide 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × Sirolimus × Sarcoma × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡